Contact us for a free technical consultation and quote.
If you need immediate assistance, please email us at
animal-service@cyagen.com.
On behalf of our animal model experts, we invite you to request a
Cyagen One-on-One Webinar!
Animal modeling has a played a prominent role in traditional scientific research for hundreds of
years, and more recently, inbred strains have been developed to support genetically modified models
for applications in biomedical and health research. Additionally, gene-edited animal models are
widely adopted by drug R&D companies, scientific research institutions, and laboratories worldwide
in analyzing the function of disease-related genes, studying signaling pathways, identifying drug
targets, screening new drugs, and more.
With these webinar opportunities, Cyagen’s expert team will comprehensively explain the cutting-edge
technology, academic hotspots, and application limitations of animal models - such as genetically
modified, humanized, and immunodeficient mice - from various perspectives, as we aim to exchange and
share valuable experiences with you and your team.
Fill out the form to customize your webinar!
Cyagen's Animal Model Experts and Main Lecture Themes
Theme 1
Applications of Genetically Modified Mice in Translational Medicine
| Main Topics |
|
|
●
Strategies and methods of different gene-editing technologies
|
|
●
The application of humanized mouse models in drug discovery
|
|
●
In-depth explanation of the animal models in hot research areas -
Immunity, Cardiovascular, Oncology, Metabolism, Neurology
|
|
●
AlphaKnockout gene-targeting system and corresponding AI
Knockout Mouse Model eBank
|
|
●
Applications of germ-free mice in the interconnected
mechanisms of gut microbes and immunity
|
| Lecturer |
|
Dr. Steve Yu
Senior Vice President and Senior Scientist
|
|
Dr. Steve Yu has more than 20 years of experience in the field of genetically modified
animal models from both R&D and management roles. As an internationally renowned expert
in model animals and cell biology, Dr. Yu successively served in Yale School of Medicine
and NYU Grossman School of Medicine, inGenious Targeting Laboratory (iTL), Applied
StemCell (ASC) and other institutions in the field of genetically modified animal
models. Currently, Dr. Yu is working for Cyagen as Senior Vice President and Senior
Scientist, primarily responsible for the technical development of genetically modified
animal model platforms. His research results have been published in high-impact journals
such as Nat Immunol and Mol Cell Biol.
|
Theme 2
Overview of Cyagen Small Animal Surgical & Disease Model Services - From Gene to Phenotype
|
Main Content
|
|
|
●
Translating drug discovery to clinical applications: how to cross the valley of death?
|
|
●
How to prepare complex and elaborate small animal disease models:
|
1. Model of Myocardial Ischemia/Reperfusion Injury
2. Pulmonary Hypertension (PHTN) Model and Hemodynamics Test
3. Embolic Middle Cerebral Artery Occlusion (MCAO)
4. Transverse Aortic Constriction (TAC)
5. Acute Kidney Injury (AKI)
6. Digestive Surgery
|
|
●
Experience and case analysis
|
| Lecturer |
|
Dr. Rongli Zhang
Chief Scientist of Cyagen Surgical Disease Models
|
|
Dr. Rongli Zhang has more than 20 years of experience in creating mouse surgical models.
Prior to Cyagen, Dr. Zhang was employed by China Academy of Chinese Medical Science
(CACMS), Tsinghua University (THU), Peking University (PKU) and other internationally
renowned academic institutions after earning his PhD. Since 2011, he has worked in Case
Western Reserve University in the U.S. as both a research scientist and as director of
the Cardiovascular Physiology Laboratory, where he leads the discovery of disease
phenotypes in genetically engineered animals and preclinical drug development. In
addition, he has done many preclinical pharmacology studies for domestic and worldwide
pharmaceutical enterprises - helping these companies achieve successful product
launches. Dr. Zhang has finished 10 projects during his work in China and took part in
multiple fund programs in the U.S. supported by both the NIH (National Institutes of
Health) and AHA (American Heart Association). He has 60 publications in SCI journals,
with many articles published in high-impact academic journals (such as Nature,
Proceedings of the National Academy of Sciences, Journal of Clinical Investigation,
Circulation, Cell, Nature Communications, and Science Translational Medicine).
|
|
|
As a global leader in animal model services, Cyagen provides major gene knockout (KO),
gene knockin (KI), conditional knockout (cKO), humanization, and other model
customization services in superior quality and full guarantee. Additionally, Cyagen has
established its self-developed pharmaceutical R&D lines - catering to drug development
and screening in the field of cancer, immunity, endocrine system, cardiovascular system,
infectious diseases, and more. In the spirit of continual progress, the company has also
built several new platforms for antibody drug development on the basis of humanized
mouse antibodies, Germ-free (GF) based microbial drug R&D technology, and mouse
phenotype analysis. Cyagen’s products and services have been cited in over 3,600 papers
cross highly reputed publications and journals including Cell, Nature, Science
and more - all in under 15 years.
|
